期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Bcl-6和CD10蛋白在弥漫大B细胞淋巴瘤中的表达及临床意义 被引量：2

Expressions and clinical significances of Bcl-6 and CD10 in Diffuse Large B-cell Lymphomas
下载PDF
导出
摘要 目的探讨Bcl-6和CD10蛋白在弥漫大B细胞淋巴瘤(DLBCL)中的表达及临床意义。方法应用免疫组织化学方法检测62例弥漫大B细胞淋巴瘤标本及20例淋巴结反应性增生(RLH)石蜡组织中Bcl-6、CD10蛋白的表达,结合随访资料进行临床预后分析。结果Bcl-6、CD10在弥漫大B细胞淋巴瘤中均有表达,阳性率分别为82.26%(51/62)、38.71%(24/62),显著低于淋巴结反应性增生中的阳性率100%(52/52)、100%(52/52),差别有显著性(P(0.05);Bcl-6的表达与生存期相关,生存期大于5年组中Bcl-6的阳性率为87.50%(21/24),明显高于生存期小于5年组中Bcl-6阳性率50.00%(19/38)(P(0.05)。Bcl-6的表达与弥漫大B细胞淋巴瘤患者的临床分期、B症状、结外浸润、治疗结果差别无统计学意义(P(0.05);CD10的表达与弥漫大B细胞淋巴瘤患者的临床分期相关,临床分期越低,CD10阳性表达越高。生存期大于5年组中CD10的阳性率为75.00%(18/24),显著高于生存期小于5年组中CD10阳性率15.79%(6/38)(P(0.05)。CD10的表达与弥漫大B细胞淋巴瘤患者的B症状、结外浸润、治疗结果差别无统计学意义(P(0.05);CD10阳性表达者大部分同时表达Bcl-6,但在部分CD10表达阴性的病例中,Bcl-6也呈阳性表达,Bcl-6、CD10共表达组比非共表达组临床分期低,生存率高于非共表达组。结论Bcl-6、CD10在弥漫大B细胞淋巴瘤中均与生存期成正相关,是预后良好的指标,二者联合检测有助于判断患者的预后和指导临床治疗。 Objective To investigate the expressions and clinical significances of Bcl-6 and CD10 in Diffuse Large B-ceU Lymphomas （DLBCL）. Method The expressions of bcl-6 and CD10 were evaluated in 62 cases of Diffuse Large B-cell Lymphoma and 20 cases of reactive lymphoid hyperplasia（RLH） by means of immu- mohistochemistry. Results （ 1 ） The expressions of bcl-6 and CD10 were detected in DLBCL and the expression rates were 82.26% and 38.71%, respectively. （2）The expression of Bcl-6 was related with overall survival, which was higher in Bcl-6 positive DLBCLthan that in Bcl-6 negative DLBCL（ P 〈0.05）. The expression of bcl- 6 was not correlated with clinical stages, B-symptoms, extranodal infiltrations and therapeutic results of DLBCL. （3） The patients with CD10 positive DLBCL had a lower stage of disease than patients with CD10 negative DL- BCL. And the survival analysis showed a trend for a longer overall survival duration in the CD10 positive group compared with the CD10 negative group （P 〈 0.05 ）. The expression of CD10 was not correlated with B-symp- toms, extranodal infiltrations and therapeutic results of DLBCL. （4） The clinical stage of the group with coexpres- sion of Bcl-6 and CD10 was lower than the group with non-coexpression and had higher overall survival. Conclu- sion Bcl-6 and CD10 were related with overall survival and may be markers of favorable prognosis in DLBCL, so the detections of the coexperssion of the Bel-6 and CDI0 protein will contribute to predict the prognosis of the DLBCL.
作者 王金彩 张清媛 赵文辉
机构地区 哈尔滨医科大学附属肿瘤医院内三科
出处 《实用肿瘤学杂志》 CAS 2008年第5期412-416,共5页 Practical Oncology Journal
关键词 弥漫大B细胞淋巴瘤(DLBCL) BCL-6 CDIO Diffuse Large B- cell Lymphoma（DLBCL） Bcl-6 CD10
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Ye BH, Rao PH, Chaganti RS, et al. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma[ J], Cancer Res, 1993,53:2732- 2735.
  • 2姜文奇.恶性淋巴瘤的生物治疗[C],第三届中国肿瘤学大会.
  • 3Dent AL, Vasanwala FH, Toney LM. Regulation of gene exp ression by the proto-oncogene bcl-6 [ J ]. Crit RevOncol Hematol, 2002, 41:1-9.
  • 4Burglund M, Thunberg U. Evaluation of immunophetype in diffuse large B-cell lymphoma and its impact on prognosis. [ J]. Mod Patho1,2005.
  • 5揭伟,申志华,郭瑞珍,肖庆邦.非霍奇金淋巴瘤中Bcl-6的表达及意义[J].广东医学院学报,2003,21(3):210-212. 被引量：9
  • 6Hans CP,Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J]. Blood, 2004,103:275-282.
  • 7Xu Y, McKenna RW. The t(14;18) in diffuse large B-cell lymphoma: correlation with germinal center-associated markers and clinical features [ J]. Appl Immunohistochem Mol Morphol,2005.

二级参考文献9

  • 1Ye BH,Rao PH,Chaganti RS,et al. Cloning of Bcl-6,the locus involved in chromosome translocation affecting band 3q27 in the B-cell neoplasm[J]. Cancer Res, 1993, 53(12):2732-2735.
  • 2Ree HJ ,Kadin ME ,Kkuchi M,et al. Bcl-6 expression in reactive follicular hyperplasis, follicular lymphoma, and angioimmunoblastic T-cell lymphoma with hyperplastic geminal centers:heterogensis of intrafollicular T-cell and their altered distribution in the pathogenesis of angioimmunoblastic T-cell lymphoma [J]. Hum Pathol, 1999, 30(4) :403-411.
  • 3Flenghi L, Ye BH, Fizzotti M,et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells[J]. Am J Pathol, 1995,147(2) :405-407.
  • 4Dogan A, Bagdi E, Munson P, et al. CD 10 and Bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas [J]. Am J Surg Pathol, 2000, 24(6):846-852.
  • 5Gaidano G,Capello D,Gloghini A,et al. BCL-6 in AIDS-related lymphoma:pathogenetic and histogenetic implications[J], Leuk Lymphoma, 1998,31 (1-2) : 39-46.
  • 6Hyjek E,Chadburn A,Liu YF,et al. BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus [J]. Blood, 2001,97 ( 1 ):270-271.
  • 7Muramatsu M, Akasaka T, Kadowaki N, et al. Rearrangement of the bel-6 gene in B-cell lymphoid neoplasms :comparison with lymphomas associated with bel-2 rearrangement[J]. Br J Haematol, 1996,93(4) : 911-920.
  • 8陶琨,朱雄增,徐薇苓,陈忠伟,陆洪芬.原癌基因bcl-6在淋巴组织增生性疾病中表达及意义[J].临床与实验病理学杂志,2000,16(2):93-95. 被引量：4
  • 9翟琼莉,张连郁.bcl-2、bcl-6在非霍奇金淋巴瘤中的表达及其与临床行为特征的相关性研究[J].中华肿瘤杂志,2001,23(2):144-145. 被引量：9

共引文献8

同被引文献58

  • 1Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T - cell lymphoma: a proposed clinical - path- ologic prognostic score [ J ]. J Clin 0ncol, 2006,24 ( 16 ) : 2472 - 2479.
  • 2Mourad N, Mounier N, Bribre J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T- cell lymphoma treated within the Groupe d'Etude des Lymphomes del Aduhe (GELA) trials [ J ]. Blood, 2008,111 (9) : 4463 - 4470.
  • 3Attygalle A, M -Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T - cell lymphoma express CD10 [ J ]. Blood, 2002,99 (2) : 627 - 633.
  • 4Kim CH, Lim HW, Kim JR, et al. Unique gene expression program of human germinal center T helper cells [ J ]. Blood,2004,104(7) : 1952 - 1960.
  • 5Tsuchiya T, Ohshima K, Karube K, et al. Thl ,Th2, and acti- vated T -cell marker and clinical prognosis in peripheral T - cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL [ J ]. Blood, 2004,103 ( 1 ) :236 - 241.
  • 6Karubo K, Aoki R, Nomura Y, et al. Usefulness of flow cy- tometry for differential diagnosis of precursor and peripheral T- cell and NK -cell lymphomas: analysis of 490 cases [J]. Pathol Int,2008,58(2) :89 -97.
  • 7Karube K, Suzumiya J, Okarnoto M, et al. Adult T - cell lymphoma/leukernia with angioimmunoblastic T - cell lym- phomalike features: Report of 11 cases [ J ]. Am J Surg Pathol, 2007,31 (2) :216 - 223.
  • 8Chen W, Kesler MV, Karandikar NJ, et al. Flow cytometric features of angioimmunoblastie T - cell lymphoma [J]. Cy- tometry B Clin Cytom ,2006,70 (3) : 142 - 148.
  • 9Dupuis J, Boye K, Martin N, et al. Expression of CXCLB by neoplastic cells in angioimmunoblastie T -cell lymphoma (AITL) :a new diagnostic marker providing evidence that AITL derives from follicular helper T cells [ J ]. Am J Surg Pathol,2006,30 (4) : 490-494.
  • 10Grogg KL, Attygale AD, Macon WR, et al. Expression of CXCLB, a chemokine highly up regulated in germinal cen- ter T - helper cells, distinguishes angioimmunoblastic T - cell lymphoma from peripheral T - cell lymphoma, unspec- ified[J]. Mod Pathol,2006,19 (8) : 1101 - 1107.

引证文献2

二级引证文献2

实用肿瘤学杂志
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部